title: [Local treatment combined with EGFR-TKIs for advanced non-small cell lung cancer with solitary progression during EGFR-TKI treatment].
abstract: OBJECTIVE
  Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are routine treatments for non-small cell lung cancer (NSCLC) with EGFR mutation. Different clinical modes can be used to treat patients with TKI resistance, one of which is solitary progression. The aim of this study is to analyze available treatments for patients undergoing solitary progression.
  
  
  METHODS
  Clinical data of 45 patients with advanced NSCLC who received local radiotherapy combined with EGFR-TKI after solitary progression were reviewed and analyzed.
  
  
  RESULTS
  Among the 45 patients, 11 showed partial response, 23 achieved stable disease state, and 11 experienced progressive disease. The median of progression-free survival (PFS) was 5.9 months.
  
  
  CONCLUSIONS
  Local therapies combined with EGFR-TKIs can prolong the PFS of patients with NSCLC who exhibited solitary progression during EGFR-TKI treatment.
authors.affiliation: Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China.
authors.forename: Xin
authors.initials: X
authors.lastname: Zhang
authors.forename: Bin
authors.initials: B
authors.lastname: Wang
authors.forename: Lin
authors.initials: L
authors.lastname: Lin
authors.forename: Xuezhi
authors.initials: X
authors.lastname: Hao
authors.forename: Shanshan
authors.initials: S
authors.lastname: Chen
authors.forename: Junling
authors.initials: J
authors.lastname: Li
authors.forename: Xiangru
authors.initials: X
authors.lastname: Zhang
authors.forename: Yuankai
authors.initials: Y
authors.lastname: Shi
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology / Q000532:radiotherapy; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D066246:ErbB Receptors; D000077156:Gefitinib